Ethos Technologies Inc. (LIFE) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ethos Technologies Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.069 -- 00:00:04.332 Good afternoon, ladies and gentlemen, and welcome to the Atire Pharma fourth quarter 00:00:04.332 -- 00:00:09.855 and full year 2023 conference call. At this time, all participants are in a listen-only 00:00:09.855 -- 00:00:14.778 mode. Later, we will conduct a question and answer session, and instructions will be 00:00:14.778 -- 00:00:19.601 given at that time. To ask a question during the session, please press star 1-1 on your 00:00:19.601 -- 00:00:22.343 telephone and wait for your name to be announced. 00:00:22.343 -- 00:00:25.685 To withdraw your question, please press star 1-1 again. 00:00:25.685 -- 00:00:29.764 As a reminder, this conference is being recorded for replay purposes. 00:00:29.764 -- 00:00:35.167 It is now my pleasure to hand the conference call over to Ashley Dunstan, ATAR's Director 00:00:35.167 -- 00:00:37.808 of Investor Relations and Public Affairs. Ms. 00:00:37.808 -- 00:00:40.589 Dunstan, you may begin. 00:00:41.310 -- 00:00:46.132 Thank you, and good afternoon, everyone. Thank you for joining us today to discuss ATAR's 00:00:46.132 -- 00:00:51.055 fourth quarter and full year 2023 operating results and corporate update. 00:00:51.055 -- 00:00:55.357 We are joined today by Dr. Sanjay Shukla, our President and CEO, and Ms. 00:00:55.357 -- 00:01:00.434 Jill Broadfoot, our CFO. On the call, Sanjay will provide an update on our 00:01:00.434 -- 00:01:04.737 corporate strategy, including our clinical program for ExoFitimod and research and discovery 00:01:04.737 -- 00:01:09.721 programs. Jill will review our financial results and our current financial position before 00:01:09.721 -- 00:01:13.183 handing it back to Sanjay to open the call up for any questions. 00:01:13.183 -- 00:01:17.326 Before we begin, I would ...